View this email in your browser
Share Share
Tweet Tweet
Forward Forward


Bringing you our latest news, features and guidance.
February 2021
COVID-19NewsInto practice  | Get involved | Blogs | Events 


Updated rapid guidelines on COVID-19:

Critical care in adults
We’ve added recommendations to section 4, clinical decision making and management, following publication of NHS England’s interim commissioning policies on tocilizumab and sarilumab.

Delivery of systemic anticancer treatments
We’ve added:

  • information on vaccination status to recommendation 3.3
  • emphasised the importance of reaching a shared decision, in recommendation 4.5
  • 2 research recommendations.
Delivery of radiotherapy
Following an evidence review of the effects of systemic anticancer treatment or radiotherapy on the risk of severe illness or death in patients with cancer and COVID-19, we’ve added 3 research recommendations.

Haematopoietic stem cell transplantation
We’ve added a recommendation (1.8) on vaccination and amended recommendations on:
  • when to defer donations and haematopoietic stem cell transplantation for donors (recommendations 4.1, 4.3, 4.8 and 4.10) and recipients (recommendations 3.3, 3.5 and 3.6) pre-transplant
  • guidance for staff who are self-isolating (recommendation 6.2).
View all COVID-19 guidance


NICE to launch new 5-year strategy

Our new strategic plan will set out how we’ll be more dynamic and responsive in our work. Find out what this means for you at our virtual launch event on Monday 19 April 2021.

Register to attend launch event
A pregnant person holding her belly with both hands

Treatment options for severe pregnancy sickness recommended in draft guidance

Pharmacological antiemetics, acupressure and intravenous fluids have been recommended to treat extreme cases of nausea and vomiting in pregnancy.

Our draft guidance is open for consultation until Wednesday 24 March.

A mature woman coughing and holding her chest.

Thousands of lung cancer patients to benefit from life-extending treatment

We have approved a potentially life-extending treatment for some people with non-squamous, non-small-cell lung cancer. Pembrolizumab with pemetrexed and platinum chemotherapy will become available as a first-line treatment option for adults whose tumours have no epidermal growth factor receptor (EGFR)-positive or anaplastic lymphoma kinase (ALK)-positive mutations. Around 3,000 people will be eligible for this treatment in England.

Read more news stories

Presenting a case for change: reviewing our processes for health technology evaluation

We are consultating on proposals to change the processes we use for the evaluation of medicines, medical devices, diagnostics and digital health technologies.

The proposals explore opportunities for:

  • aligning the current guidance programme processes
  • new process improvements and ways of working
  • improving the commercial and managed access processes
  • making the criteria for selecting topics for evaluation through NICE’s Highly Specialised Technologies Programme clearer.

The consultation is open until Tuesday 15 April 2021.

We are also holding a consultation event. Join this online session to learn more about the proposals: 

  • Thursday 25 February 2021, 4pm to 5pm. 
Comment on NICE's process review consultation

Assessing the resource impact of NICE guidance: process manual updated

We've updated our assessing resource impact process manual, making it clearer and easier to use. The manual describes the processes we follow to estimate the resource impact of NICE guidance.

  • Streamlined the manual into a single document. Previously, we had 2 separate manuals: one for guidelines and one for health technology assessments and highly specialised technologies.
  • Included new information on the processes for assessing resource impact for medical and diagnostic technologies.
  • Updated the presentation of the resource impact assessment tools to better meet user needs.
NICE Talks logo

How does NICE work with patients and patient groups?

In this episode, we look at how our Public Involvement Programme works and discover what it's like to be a patient representative on a committee. We talk to Laura Norburn, senior operations manager for NICE's Public Involvement Programme and Jo Jerrome, chief executive of Thrombosis UK.

Into practice

The generic NICE impact cover of the series of reports

New impact report on cardiovascular disease (CVD) management

Our latest impact report considers how evidence-based guidance has contributed to improvements in the care of people with CVD. Judith Richardson, NICE’s acting director for health and social care, has written a blog about the report in the National Health Executive.

NICE impact reports look at how implementation of our evidence-based guidance is improving health and wellbeing.

 View CVD management impact report

Get involved

What would you like to know more about?

To help us tailor our communications to meet your needs, we'd like to know which aspects of NICE's work you'd like to hear more about. Complete a short survey to share your views.

Answer 3 quick questions

Comment on a consultation

Our current consultations include:

Consultation is a key part of our guidance development process. It enables those with an interest in our guidance to comment at specific stages and feedback into the decision-making process.
See all our open consultations

Join a committee

We have a number of current vacancies for health and social care professionals, and lay people, to join our committees. Topics include multiple sclerosis, lung cancer and weight management. Join and have an active role in producing a guideline or quality standard.

See our current committee vacancies

Observe a meeting

Due to the coronavirus pandemic, we're currently holding all our public meetings virtually. You'll need to register in advance to join. 

Upcoming public meeting:

  • Monday 15 and Tuesday 16 March 2021 – Public health advisory committee E
    Reducing sexually transmitted infections
    Registration closes Monday 1 March 2021.
    Agenda and register here
  • Monday 22 and Tuesday 23 March 2021 – Public health advisory committee B
    Mental wellbeing at work
    Registration closes Monday 8 March 2021.
    Agenda and register here
Our advisory committee meetings, technology appraisal appeal hearings and public board meetings are open to the public. Holding them in public supports our commitment to having processes in place that are rigorous, open, and transparent.
See all our public meetings


‘Extending the QALY’ research project

Bhash Naidoo, NICE’s senior technical adviser in health economics, tells us about a 3-year research project he’s involved with called ‘Extending the QALY’. The research team is investigating how quality of life measures used to evaluate healthcare treatments can be extended into areas of social care and public health.

Read more of our latest blog posts


HTAi 2021 virtual annual meeting: second call for abstracts

Health Technology Assessment international’s (HTAi) annual meeting will take place on:

  • Saturday 19 to Wednesday 23 June 2021.

The event, which was scheduled to be held in Manchester, will now be fully virtual.
A second call for oral and poster abstracts is now open. HTAi is looking for submissions on the main theme ‘Innovation through health technology assessment (HTA)' and 3 plenary themes:

  • evidence for HTA: innovative methods for challenging times
  • patients at the heart of innovation
  • innovating HTA to support novel interventions.

The deadline for submissions is Monday 1 March 2021. 

Submit your HTAi abstract

NICE public board meeting

Our next public board meeting provides an opportunity to hear from our board and executive team. They’ll be sharing the latest updates about our work and will take your questions.
Our next meeting is scheduled:

  • Wednesday 24 March 2021, 1:30pm to 4:00pm, through Zoom.
Register to attend our virtual public board meeting

unsubscribe from this list